金双歧辅助治疗小儿扁桃体炎的临床研究  

Adjuvant therapy of Live Combined Bifidobacterium and Lactobacillus Tablets in children with tonsillitis

作　　者：余霞辉[1] 舒红文[1] 罗健[1] 常洪美[2] 邓骥[1] 邱有波[1] 宋昔兰 薛成[3] 

机构地区：[1]崇州市人民医院儿科,四川崇州611230 [2]崇州市人民医院院感科,四川崇州611230 [3]崇州市人民医院检验科,四川崇州611230

出　　处：《中国微生态学杂志》2016年第2期169-173,共5页Chinese Journal of Microecology

基　　金：成都市科技局科技惠民计划立项的科研课题(2013-HMO1-3-00004-SF)

摘　　要：目的探讨金双歧(双歧杆菌乳杆菌三联活菌片)辅助治疗小儿扁桃体炎的疗效及安全性。方法纳入2013年1月至2014年7月在崇州市人民医院儿科住院诊断为扁桃体炎患儿337例,用随机数字表随机分为试验组和对照组。试验组在常规给予抗生素和对症治疗的基础上,给予金双歧口服辅助治疗,出院后继续服用4周;对照组常规给予抗生素和对症治疗。观察并比较两组患儿的临床效果,住院期间发生抗生素相关性腹泻的差异。出院后3个月内定期随访,观察两组患儿出院后3个月内发生呼吸道感染和肠道感染的差异。结果试验组治疗后总有效率为98.00%,对照组治疗后总有效率为93.33%。试验组总有效率明显优于对照组,差异有统计学意义(χ2=3.940,P=0.047<0.05)。住院期间试验组抗生素相关性腹泻发生率为8.67%,对照组为19.33%,差异有统计学意义(t=7.087,P=0.008<0.01)。出院后3个月内呼吸道感染以及肠道感染的发生率试验组低于对照组,差异有统计学意义(1个月肠道感染χ2=4.624,呼吸道感染χ2=8.549;2个月肠道感染χ2=5.684,呼吸道感染χ2=11.712;3个月肠道感染χ2=7.545,呼吸道感染χ2=4.559,P<0.05)。试验组服用金双歧期间,未见明显药物相关不良反应。结论金双歧辅助治疗小儿扁桃体炎可提高临床疗效,降低抗生素相关性腹泻的发生率,降低扁桃体炎患儿出院3个月内呼吸道和肠道感染的发生率,且服用安全。Objective To explore the efficacy and safety of Live Combined Bifidobacterium and Lactobacillus Tablets（LCBLT）in children with tonsillitis.Methods 337 children with tonsillitis were included and randomly divided into experimental group or control group.The experimental group was given LCBLT as the adjuvant therapy based on regular antibiotics and symptomatic treatment,and the adjuvant therapy continued for 4weeks after discharge.The control group was given regular antibiotics and symptomatic treatment only.The clinical efficacy,incidence of antibioticassociated diarrhea during hospitalization,and the incidences of respiratory tract infection and intestinal infection within3 months since discharge were observed and compared between the two groups.Results The total efficiency in the experimental group was significantly superior to that in the control group（98.00%vs 93.33%,P〈0.05）.The incidence of antibiotic-associated diarrhea during hospitalization in experimental group was significantly lower than that in the control group（8.67%vs 19.33%,P〈0.01）.The incidence of respiratory infection and intestinal infection within three months since discharge in experimental group was lower than that in control group,and the difference was of statistical significance（P〈0.05）.There was no significant drug-related adverse reactions in the experimental group during administration of LCBLT.Conclusion The adjuvant therapy of LCBLT is safe for treatment of tonsillitis,which can improve the clinical efficacy,lower the incidences of antibiotic-associated diarrhea,respiratory infections and intestinal infections within three months after discharge among children with tonsillitis.

关 键 词：双歧杆菌乳杆菌三联活菌片 扁桃体炎 儿童 益生菌 

分 类 号：R776.18[医药卫生—眼科]